clinical trial · NCT07297797
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
Fujian Shengdi Pharmaceutical Co., Ltd.·phase2·active not recruiting·n = 238
Mild to Moderate HypertensionHRS-9563 Injectionsodium chloride injection
brief summary
This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
started
Jan 14, 2026
primary completion
Dec 1, 2026
completion
Oct 1, 2027
last updated
Jul 31, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol